The Lancet Oncology - The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks to assess the benefits of cancer therapies.

A group of scientists applied these frameworks to a cohort of contemporary randomised controlled trials to explore agreement between the two approaches and to assess the relation between treatment benefit and cost.

 

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks

 

Authors: Joseph C Del Paggio, Prof Richard Sullivan, Prof Deborah Schrag, Wilma M Hopman, Biju Azariah, Prof C S Pramesh, Prof Ian F Tannock, Dr Christopher M Booth

The Lancet Oncology - DOI: http://dx.doi.org/10.1016/S1470-2045(17)30415-1 - 02 June 2017